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Abstract
Background: A variety of psychological interventions to treat depressive disorders have been developed and are
used in primary care. In a systematic review, we compared the effectiveness of psychological treatments grouped
by theoretical background, intensity of contact with the health care professional, and delivery mode for depressed
patients in this setting.
Methods: Randomized trials comparing a psychological treatment with usual care, placebo, another psychological
treatment, pharmacotherapy, or a combination treatment in adult depressed primary care patients were identified
by database searches up to December 2013. We performed both conventional pairwise meta-analysis and network
meta-analysis combining direct and indirect evidence. Outcome measures were response to treatment (primary
outcome), remission of symptoms, post-treatment depression scores and study discontinuation.
Results: A total of 37 studies with 7,024 patients met the inclusion criteria. Among the psychological treatments
investigated in at least 150 patients face-to-face cognitive behavioral therapy (CBT; OR 1.80; 95 % credible interval
1.35–2.39), face-to-face counselling and psychoeducation (1.65; 1.27–2.13), remote therapist lead CBT (1.87; 1.38–2.53),
guided self-help CBT (1.68; 1.22–2.30) and no/minimal contact CBT (1.53; 1.07–2.17) were superior to usual care or
placebo, but not face-to-face problem-solving therapy and face-to-face interpersonal therapy. There were no statistical
differences between psychological treatments apart from face-to-face interpersonal psychotherapy being inferior to
remote therapist-lead CBT (0.60; 0.37–0.95). Remote therapist-led (0.86; 0.21–3.67), guided self-help (0.93; 0.62–1.41) and
no/minimal contact CBT (0.85; 0.54–1.36) had similar effects as face-to-face CBT.
Conclusions: The limited available evidence precludes a sufficiently reliable assessment of the comparative
effectiveness of psychological treatments in depressed primary care patients. Findings suggest that psychological
interventions with a cognitive behavioral approach are promising, and primarily indirect evidence indicates that it
applies also when they are delivered with a reduced number of therapist contacts or remotely.
Systematic review registration: 01KG1012 at http://www.gesundheitsforschung-bmbf.de/de/2852.php
Background
Psychological interventions have a central role in the
treatment of depressive disorders as an alternative to or
a combination with antidepressant drugs [1–4]. A variety
of therapies have been developed based on cognitive-
behavioural, interpersonal, psychodynamic, or humanis-
tic approaches. A recent large network meta-analysis of
198 randomized trials in patients with depression [5]
found that while the amount and the robustness of evi-
dence varied across the single therapies the clinical ef-
fects seemed to be similar in size. Most of the trials
included in this large meta-analysis were performed in
specialized mental health care settings. In relation to
treatment of depression in primary care two main ques-
tions arise. First, can we extrapolate the findings from
trials in specialized settings to primary care? Patients
with depression in primary care sometimes have less se-
vere [6–8] and more somatic symptoms [9, 10] than
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patients referred to specialty mental health care. Second,
the limited number and the regional distribution of quali-
fied professionals make it difficult to provide personalized
multi-session face-to-face psychological therapies on a
population-wide level. Therefore, a number of interven-
tions have been developed in which the contact time with
health care professionals is reduced and/or in which the
treatment is delivered by telephone, electronically, or by
using printed materials. It is crucial to know how these
less resource intensive methods of providing psycho-
logical treatments compare to the more intense “trad-
itional” interventions.
We recently reported a systematic review and meta-
analysis of 30 randomized trials comparing psycho-
logical treatments with usual care or placebo controls
in depressed primary care patients [11]. Psychological
treatments were superior to usual care. Effects of tele-
phone- or internet-based and of reduced minimal con-
tact cognitive behavioural approaches were broadly
similar to those of personalized therapies. However, as
trials had to include a usual care or placebo control
group in that analysis, we excluded trials and contrasts
comparing active treatments (psychological therapy,
pharmacotherapy, or combination of both) with each
other. Furthermore, indirect comparison of effect sizes
derived from conventional meta-analyses of trials with
usual care controls is methodologically problematic
[12]. Network meta-analysis provides an approach to
estimate effect sizes for all possible pairwise compari-
sons whether or not they have been compared head to
head in trials making efficient use of all available evi-
dence [13]. Thus, in the current study we utilized con-
siderably more data than in our previous review [11]
and made use of the method of network meta-analysis
in order to estimate the comparative effectiveness of
psychological treatments formally. By doing so, we were
not only able to increase the precision of our previous
estimates on comparisons with control treatments but
also to provide effect size estimates for all pairwise
comparisons and to test whether the evidence base is
consistent (i.e., whether pieces of information from
various sources such as direct and indirect comparisons
agree with each other). Correspondingly, amending our
previous dataset [11] with head to head comparisons,
here we report a network meta-analysis of randomized
trials in primary care patients with depression to compare
the effectiveness of psychological treatments grouped
by theoretical background, intensity of contact with the
health care professional, and delivery mode.
Methods/design
Protocol
Details of the methods have been described in our pub-
lished protocol [14] and in our conventional meta-
analysis [11]. Within the overall project we also reviewed
trials comparing antidepressant drugs among each other
or with placebo [15].
Literature search, study selection, assessment of risk of
bias, and data extraction
We searched Medline, Embase, Cochrane Central Register
of Controlled Trials (CENTRAL) and PsychINFO (main
search June 2011, last update searches December 2013;
see on-line supplemental material, section 1.1, for the
complete Medline search strategy (Additional file 1)). We
searched trial registries for unpublished and ongoing stud-
ies, and screened published systematic reviews focusing
on primary care studies on depression treatments [16–19]
for additional trials.
A single reviewer screened search hits and excluded
clearly irrelevant records. Two reviewers independently
checked all remaining records against inclusion criteria.
Disagreements were resolved by discussion. We in-
cluded randomized controlled trials that compared
psychological or combined psychological and pharma-
cological interventions with one another, a pharmaco-
logical intervention, usual care or placebo in the
treatment of adult primary care patients suffering from
prevalent or incident unipolar depressive disorders.
Psychological treatments were defined as interventions
that are based on a scientific theoretical background
and use psychological techniques to reduce symptoms
and improve general well-being through modifying
motivational, emotional, cognitive, behavioural or inter-
personal processes. For inclusion, they needed to be
performed either as tailored verbal communication
process between a patient (or a group of patients) and a
health care professional in direct or remote (e.g., per
phone) contact or as a less or non-guided intervention
using written information material (e.g., a book) or a
computer program that the patient worked through
more or less independently. Patients had to be recruited
through direct referral from a primary care physician,
or by systematic screening of patients in the waiting
room or listed in a primary care provider’s practice.
Trials had to report results on at least one of the follow-
ing outcomes: response to treatment, remission of symp-
toms, mean score on a depression scale (post-treatment
or change from baseline), or study discontinuation.
Information on patients, methods and results of all in-
cluded studies were extracted by at least two independ-
ent reviewers using a pre-tested form. The Cochrane
tool for assessing risk of bias was used to assess internal
validity [20]. As the included studies reported results on
efficacy in a very diverse and often incomplete manner,
we performed an additional extraction round for extract-
ing or imputing outcome data (see on-line supplemental
material, section 1.2 for how outcomes were selected
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(Additional file 1)). This additional extraction was done
by one experienced reviewer, while a second experienced
reviewer cross-checked all extracted data and re-calculated
imputations.
Classification of treatments
We classified treatments consistently with our previous
work [11] (pages 58–59): “As psychological treatments
are considered complex interventions [21], grouping
them can be performed along several dimensions and re-
mains controversial [22]. Our classification system was
largely pre-specified and followed published models [5],
but needed some modification to account for the clinical
heterogeneity in the identified primary studies. We
grouped interventions according to the following dimen-
sions: (1) theoretical background: cognitive behavioural
therapy (CBT) vs. problem solving therapy (PST) vs.
interpersonal therapy vs. psychodynamic therapies vs.
other interventions; (2) intensity of contact with health
care professional: intensively therapist-lead (with a mini-
mum of six sessions) vs. guided self-help (with less than
six sessions with the therapist) vs. no or minimal contact
(with less than 90 minutes contact) interventions; and
(3) face-to-face vs. remote contact interventions. Al-
though not all dimensions of this classification system
are completely independent and not all possible combi-
nations present realistic alternatives, we considered it
both comprehensive and sophisticated enough to de-
scribe reasonably differentiated treatment options that
may be present in everyday care and may be relevant to
health policy decision-making concerning primary care
patients with depression.” Pharmacological treatments
were categorized into substance classes, while usual care
and placebo treatment were considered as reasonably
comparable reference treatments (for example, sup-
ported by [5]).
Outcomes
The pre-specified primary efficacy endpoint was response
to treatment (an at least 50 % score reduction on a
depression scale from baseline). Secondary outcomes
were remission (defined as having a symptom score
below a fixed threshold) and post-treatment depression
scores. Study discontinuation was used as an indicator of
acceptability. For participants with missing data, imputed
estimates were used as reported by the trial authors. If
imputed estimates were unavailable, participants with
missing data were considered non-responders. In cases
where responder and remission data was not reported, it
was imputed from means and standard deviation using
the method described by Furukawa et al. [23]. For re-
sponse imputation, first the threshold of at least 50 %
score reduction after completion of treatment was de-
fined by halving the mean baseline score. Then, the
proportion of participants reaching this threshold was
calculated assuming a normal distribution of the data
after completion of treatment. Further details, examples,
and empirical justification are given by Furukawa et al.
[23] and Meister et al. [24]. For our main analysis, we
used data after completion of treatment.
Statistical analyses
Due to technical reasons (some of the applied software
were being developed parallel to the project), we used
both Bayesian and frequentist methods. Although these
two approaches have different philosophical back-
grounds (for example, in the Bayesian view probability
is the subjective plausibility of an event, while in the
frequentist view it is the frequency of an event in mul-
tiple repeated trials), under the here applied conditions
they largely agree in their findings, so that the hereby
introduced methodological diversity is unlikely to be a
considerable limitation [25]. For binary outcomes, we
used the odds ratio as the effect measure. Conventional
meta-analyses of pairwise direct comparisons within stud-
ies were performed using the inverse variance weighted
random effects model option in RevMan5. For network
meta-analyses of odds ratios (software WinBUGS and R
interface R2WinBUGS [http://www.r-project.org/]), a
Bayesian framework following the recommendations of
the Decision Support Unit of the National Institute of
Health and Clinical Excellence (NICE) was used to
combine direct and indirect evidence [26]. Precisely, we
used the code provided in Example 1(c) of [26] with a
vague uniform (0.5) prior for the between-study standard
deviation. For network meta-analysis of standardized mean
differences (SMD), a frequentist method was applied using
the R package netmeta [http://www.r-project.org/] [27,
28], using the generalized method-of-moments estimator
of between-study heterogeneity given in [29]. We also
calculated a generalized I2 statistic [30].
For a network meta-analysis to be valid, three assump-
tions should be met [12, 13]: 1) among trials available
for head-to-head comparison study findings should be
sufficiently homogeneous for each intervention group
(homogeneity assumption); 2) effect estimates derived
from different sources of evidence (e.g., from direct
head-to-head comparisons and from indirect compari-
sons) should be consistent (consistency assumption);
and 3) trials should be clinically sufficiently comparable
(transitivity assumption). Homogeneity and consistency
were investigated using a net heat plot [27]. In addition,
we compared the results of the consistency model with
that of an inconsistency model (the unrelated mean
effects model) using the deviance information criterion
(DIC) as a goodness of fit index [31]. The inconsistency
model differs from the consistency model primarily in
that it does not require that effect estimates for the
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same comparison from different evidence sources are
equal (while the consistency model does). If this model
fits the data considerably better than the consistency
model (for example, based on the comparison of the
DIC values), it can be concluded that the consistency
assumption (see above) is not fulfilled. Transitivity was
assessed considering clinical and methodological as-
pects following the recommendations by Salanti [13].
The potential impact of six pre-specified (risk of bias,
recruitment method, diagnostic subtype of depression,
mean age of participants, duration of treatment) and
one post hoc defined covariate (sample size) was ana-
lyzed using a meta-regression model [32]. Funnel plots
were produced for all direct comparisons with data
from at least five trials. As there were no direct com-
parisons with ten or more trials, we did not perform
statistical tests to distinguish chance from real asym-
metry (insufficient power of such tests).
Results
Results from 37 studies (reported in 44 publications)
with 7,024 patients were included in the review (see
Table 1, on-line supplemental material section 2 for
references and section 3 for trial flow chart and charac-
teristics of individual studies (Additional file 1)). 19 tri-
als recruited patients clinically after a diagnosis and
referral from the primary care physician, 16 in a screen-
ing procedure, and two used mixed approaches. 14 trials
exclusively included patients meeting diagnostic criteria
for major depression, and in 16 trials patients were either
not formally diagnosed according to standardized schemes
or patients with a variety of depressive disorders were
included. Seven trials included patients with minor de-
pression or dysthymia. The overall risk of bias was consid-
ered low in 13, unclear in 11 and high in 13 trials.
The 37 trials had randomized patients to a total of 83
treatment arms relevant to our review (Table 1). Twenty-
nine trials had two, seven trials three and one trial four
relevant treatment arms. The median treatment length
was 12 weeks (range 6–26 weeks). Based on our classifica-
tion system interventions were allocated to 16 different
classes (see Fig. 1). Forty treatment arms received a face-
to-face psychological therapy with at least six treatment
sessions: cognitive behavioural therapy (CBT) in nine
treatment arms, problem solving therapy (PST) in five,
interpersonal psychotherapy in three, psychodynamic
therapy in one, and other psychological interventions in
eight (seven of these used variable counselling interven-
tions and one a psycho-educational intervention). Six
treatment arms received a remote telephone or online
therapist-lead intervention with at least six sessions
(four trials using CBT and two using PST). In four
groups, respectively, the intervention was guided self-help
CBT or a no or minimal contact CBT intervention. Ten
groups received antidepressants (6 selective serotonin
reuptake inhibitors, SSRI, 3 tricyclic antidepressants, and
1 individualized antidepressants), 3 combinations of psy-
chological treatments (face-to-face CBT, PST, and inter-
personal psychotherapy, in one group each) and selective
serotonin reuptake inhibitors (SSRI), and 30 usual care or
a placebo. It should be noted that only very few patients
received face-to-face psychodynamic therapy (n = 26),
remote therapist-lead PST (n = 33), individualized antide-
pressants (n = 51), a combination of face-to-face CBT and
an SSRI (n = 17), or a combination of face-to-face inter-
personal psychotherapy and an SSRI (n = 35). All other in-
terventions were tested in more than 150 patients (Fig. 1).
The 16 intervention categories result in 120 possible
comparisons of treatment classes, but only 25 these
have actually been directly investigated in clinical trials.
Among these, only the comparisons of face-to-face
CBT and other face-to-face therapies with usual care or
placebo were investigated in five or more trials.
For the main outcome measure response 34 trials pro-
vided data for pairwise and network meta-analysis.
These 34 trials included a total of 51 direct comparisons:
29 comparisons of a psychological treatment with usual
care or placebo, 4 with another psychological treatment,
9 with drug treatment, 3 comparisons of a combination
of psychological treatment and pharmacotherapy with
pharmacotherapy alone, 2 of a combination treatment
and a psychological treatment alone, and 4 comparisons
between a drug and placebo (see Figures 4.1, 4.5, 4.9,
4.13, and 4.17 in the on-line supplementary material
(Additional file 1)). Response data were not available for
the two small trials investigating remote therapist-lead
PST. Therefore this treatment category could not be
included in this analysis. Although in conventional meta-
analysis some comparisons indicated moderate statis-
tical heterogeneity, in network meta-analysis we did not
find any evidence of substantial between-trial heterogen-
eity, design inconsistency, or loop inconsistency (Q = 20,
df = 28, p = 0.861, I2 = 0, DIC = 118 for consistency model,
DIC = 128 for inconsistency model). The net heat plot
showed only slight spots of inconsistency, mainly concern-
ing the contrasts between face-to-face PST, TCA, and
usual care (see on-line supplemental material section 7
(Additional file 1)). An inconsistency analysis, based on
changes of the between-designs Q statistic following
[27], located inconsistency in the comparison PST vs
UC of a three-arm study [33] that showed an exagger-
ated effect of PST vs UC (OR 4.01; 95 % confidence
interval 1.37–11.80) compared to the network estimate
of 1.40 (95 % CI 0.99–1.98). Among the nine treatment
categories investigated in at least 150 patients face-to-
face CBT (OR 1.80; 95 % credible interval 1.35– 2.39),
other face-to-face therapies (OR 1.65; 95 % CrI 1.27–
2.13), remote therapist lead CBT (OR 1.87; 95 % CrI
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1.38–2.53), guided self-help CBT (OR 1.68; 95 % CrI
1.22–2.30), and no/minimal contact CBT (OR 1.53;
95 % CrI 1.07–2.17) were superior to usual care or pla-
cebo, while differences were not found in the compari-
son of face-to-face PST and face-to-face interpersonal
therapy with reference treatments (Fig. 2 and Table 2).
Apart from the comparison between face-to-face inter-
personal therapy and remote therapist-lead CBT (OR
0.60; 95 % CrI 0.37–0.95), there were no differences
between these nine treatments. In particular, remote
therapist-led (OR 0.86; 95 % CrI 0.21–0.67), guided self-
help (OR 0.93; 95 % CrI 0.62–1.41) and no/minimal
contact CBT (OR 0.85; 95 % CrI 0.54–1.36) had effects
similar to face-to-face CBT. 95 % credible intervals of
effect estimates for the five treatments tested only in
single small trials were very wide. We found no differ-
ences compared to usual care or placebo for four of
these (face-to-face psychodynamic therapy, individual-
ized antidepressants, combination of face-to-face PST
and SSRI and of face-to-face interpersonal psychother-
apy and SSRI). The single small trial comparing the
combination of face-to-face CBT and an SSRI (paroxe-
tine or fluoxetine) with SSRI treatment alone (which
was actually not taken by more than half of the patients)
performed in Pakistan reported very large differences
between groups. The findings of network meta-analysis
based on this trial suggest that the combination of face-
to-face CBT and an SSRI is much better than all other
treatment categories investigated, however based on in-
direct evidence only and with large imprecision (cred-
ible interval). In addition, all analyses were repeated
using the fixed effect model. The results were similar
(not shown).
In meta-regression analyses, recruitment method, age
group, risk of bias, sample size, length of treatment in
weeks, and number of sessions did not moderate treat-
ment effects, while effects were smaller in trials in
patients with minor depression and/or dysthymia (see
on-line supplemental material section 6 (Additional file
1)). Findings were broadly similar when remission or
post-treatment depression scores were used as out-
come measures instead of response (Table 2 below and
Table 3 above the diagonal; see on-line supplementary
section 4 for direct comparisons (Additional file 1)).
Table 1 Characteristics of included studies (n = 37)











Restricted to patients > 55 years 5
Diagnosis
- Major depression only 14
- Depression (mixed/not exactly specified) 16
- Mild/minor/subthreshold depression and/or dysthymia 7
Overall risk of bias
- High (high risk in one or more items) 13
- Unclear (no item high risk, < 3 low risk) 11
- Low (at least 3 low, none high risk) 13
Interventions
Psychological interventions
- Face-to-face cognitive behavioural psychotherapy (CBT;
≥ 6 sessions)
9
- Face-to-face other problem-solving treatment (PST; ≥ 6
sessions)
5
- Face-to-face interpersonal psychotherapy (≥ 6 sessions) 3
- Face-to-face psychodynamic therapy (≥ 6 sessions) 1
- Other face-to-face psychosocial interventions (≥ 6
sessions)
8
- Remote therapist-led CBT (≥ 6 sessions) 4
- Remote therapist-led PST (≥ 6 sessions) 2
- Guided self-help CBT (up to 4 contacts) 4
- No/minimal contact CBT (less than 30 minutes contact) 4
Pharmacotherapy
- Selective serotonin reuptake inhibitors (SSRI) 6
- Tricyclic antidepressants 3
- Individualized antidepressant 1
Combinations psychological interventions and
pharmacotherapy
- Face-to-face CBT + SSRI 1
- Face-to-face PST + SSRI 1
- Face-to-face interpersonal therapy + SSRI 1
Contol interventions
- Placebo 3
- Usual care 27
Median length of treatment in weeks (min., max.) 12 (6, 26)
Table 1 Characteristics of included studies (n = 37) (Continued)
Median number of treatment sessions (min., max.) 8 (0, 20)
Data available for meta-analysis
Outcome response 34
Outcome remission 34
Outcome depression score data 36
Outcome total number of patients discontinuing the study 34
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Visual inspection of funnel plots (see on-line supple-
mental material section 5 (Additional file 1)) suggested
that smaller trials tended to report more positive find-
ings for psychological treatments compared usual care/
placebo and antidepressant drugs. However, as the num-
ber of trials per treatment category was very small
funnel plots were not analysed using statistical methods.
Assessing the acceptability of treatments was possible
only in a very limited manner. The number of patients
experiencing adverse events or discontinuing the study
due to adverse events was hardly ever reported except
in studies including a drug treatment arm (and in these
studies partly only for the drug groups). Study discon-
tinuation was reported in a variable manner (drop-out
Fig. 1 Network of available comparisons. Numbers in parentheses indicate the number of trials/number of patients in which the respective
intervention was investigated. Abbreviations: CBT = cognitive behavioral therapy; PST = problem solving therapy; TCA = tricyclic and tetracyclic
antidepressants; SSRI = selective serotonin reuptake inhibitors
Fig. 2 Estimates (odds ratios and 95 % credible intervals) from network meta-analysis for the primary outcome response compared to usual care/
placebo control groups. MCMC =Markov chain Monte Carlo estimation [26]; OR = odds ratio. Abbreviations: CBT = cognitive behavioral therapy;
PST = problem solving therapy; TCA = tricyclic and tetracyclic antidepressants; SSRI = selective serotonin reuptake inhibitors; UC = usual care
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Table 2 Pairwise treatment comparisons from network meta-analyses for the outcomes response (main outcome measure, above the diagonal) and remission of symptoms
(below the diagonal)
Ftf CBT 1.26 1.61 1.05 1.09 0.96 No data 1.07 1.17 0.04 1.08 0.94 0.89 1.26 0.84 1.80
0.80–2.00 0.98–2.55 0.32–3.65 0.77–1.55 0.69–1.34 0.71–1.60 0.74–1.87 0.00–0.25 0.45–2.71 0.54–1.67 0.55–1.46 0.78–2.08 0.32–2.14 1.33–2.37
1.19 Ftf PST 1.28 0.84 0.87 0.76 No data 0.85 0.94 0.03 0.86 0.75 0.71 1.00 0.67 1.43
0.72–1.88 0.79–1.97 0.26–2.91 0.55–1.33 0.48–1.18 0.53–1.41 0.55–1.53 0.00–0.19 0.40–1.93 0.44–1.27 0.49–1.03 0.61–1.72 0.26–1.82 1.00–2.06
1.38 1.16 Ftf IPT 0.65 0.68 0.60 No data 0.66 0.73 0.02 0.67 0.59 0.55 0.78 0.52 1.11









0.80 0.67 0.58 Ftf PDT 1.04 0.91 No data 1.02 1.12 0.03 0.00–
0.31
1.03 0.90 0.85 1.20 0.80 1.71
0.22–2.95 0.18–2.38 0.15–2.08 0.32–3.35 0.27–3.11 0.31–3.30 0.31–3.67 0.26–4.50 0.27–3.02 0.28–2.58 0.33–4.32 0.18–3.42 0.53–5.78
0.88 0.74 0.64 1.09 Ftf
Other
0.88 No data 0.98 1.08 0.03 0.99 0.87 0.82 1.15 0.77 1.65
0.58–1.29 0.45–1.20 0.37–1.13 0.30–4.11 0.60–1.30 0.65–1.46 0.69–1.67 0.00–0.22 0.45–2.28 0.49–1.53 0.52–1.32 0.71–1.94 0.33–1.86 1.26–2.14
0.99 0.83 0.72 1.24 1.13 Rtl CBT No data 1.12 1.22 0.04 1.13 0.98 0.93 1.31 0.88 1.87
0.65–1.51 0.51–1.41 0.41–1.28 0.33–4.61 0.68–1.83 0.72–1.74 0.77–2.02 0.00–0.25 0.49–2.72 0.54–1.79 0.57–1.53 0.77–2.22 0.34–2.32 1.41–2.56
1.17 0.98 0.85 1.46 1.33 1.18 Rtl PST No data No data No data No data No data No data No data No data No data
0.27–4.83 0.24–4.00 0.18–3.71 0.21–9.89 0.30–5.69 0.27–5.22
0.86 0.72 0.62 1.07 0.98 0.86 0.73 Gsh CBT 1.10 0.03 1.01 0.88 0.83 1.17 0.79 1.68
0.49–1.42 0.41–1.24 0.35–1.16 0.29–4.05 0.55–1.75 0.49–1.56 0.17–3.21 0.69–1.79 0.00–0.22 0.42–2.55 0.48–1.57 0.49–1.38 0.70–2.00 0.31–2.03 1.19–2.30
1.08 0.91 0.78 1.34 1.23 1.09 0.92 1.26 Nmc
CBT
0.03 0.92 0.80 0.76 1.07 0.72 1.53
0.60–2.00 0.50–1.72 0.41–1.58 0.34–5.37 0.66–2.31 0.58–2.19 0.20–4.13 0.65–2.45 0.00–0.22 0.39–2.21 0.42–1.52 0.45–1.29 0.59–1.93 0.27–2.03 1.05–2.17
0.08 0.06 0.05 0.09 0.09 0.08 0.06 0.09 0.03 Ftf CBT +
SSRI






























0.99 0.83 0.72 1.23 1.13 1.00 0.85 1.15 0.92 13.2 Ftf PST +
SSRI
0.87 0.82 1.16 0.78 1.66
0.35–2.27 0.35–1.91 0.26–1.75 0.27–5.57 0.41–2.67 0.36–2.33 0.17–4.06 0.44–3.02 0.39–2.21 2.16–106 0.35–2.06 0.36–1.85 0.47–3.06 0.22–2.59 0.72–3.56
0.99 0.83 0.72 1.24 1.13 1.00 0.85 1.16 0.80 13.2 1.00 Ftf IPT +
SSRI
0.94 1.33 0.89 1.90
0.52–1.91 0.47–1.57 0.43–1.24 0.31–5.05 0.59–2.18 0.51–2.02 0.19–4.06 0.56–2.28 0.42–1.52 2.19–96.9 0.38–2.83 0.63–1.42 0.75–2.45 0.33–2.63 1.16–3.19
1.01 0.85 0.73 1.26 1.15 1.01 0.86 1.17 0.76 13.4 1.02 1.01 SSRI 1.41 0.95 2.02
0.61–1.64 0.57–1.23 0.48–1.12 0.37–4.43 0.70–1.91 0.60–1.74 0.20–3.72 0.68–2.03 0.45–1.29 2.57–91.3 0.47–2.43 0.57–1.69 0.84–2.50 0.37–2.54 1.37–3.00
1.03 0.86 0.75 1.28 1.17 1.04 0.88 1.20 1.07 13.7 1.04 1.04 1.02 TCA 0.67 1.43
0.59–1.75 0.50–1.42 0.45–1.25 0.35–4.75 0.66–1.97 0.59–1.83 0.21–4.35 0.66–2.26 0.59–1.93 2.52–100 0.41–2.88 0.53–1.99 0.61–1.76 0.24–1.85 0.91–2.18
0.60 0.50 0.43 0.75 0.68 0.60 0.51 0.70 0.72 7.96 0.61 0.60 0.59 0.58 Individ.
Antid.
2.13













Table 2 Pairwise treatment comparisons from network meta-analyses for the outcomes response (main outcome measure, above the diagonal) and remission of symptoms
(below the diagonal) (Continued)












3.8–161 0.69–3.96 0.86–2.76 1.05–
2.23
0.92–2.39 1.00–6.67
With regard to response, odds ratios higher than 1 favor the row-defining treatment, and odds ratios lower than 1 favor the column-defining treatment. With regard to remission, odds ratios higher than 1 favor the
column-defining treatment, and odds ratios lower than 1 favor the row-defining treatment. Reciprocals should be used to obtain odds ratios in the opposite direction. Bold-faced figures indicate a difference between
treatments with 95 % credible intervals of estimates excluding 1
Abbreviations: CBT = cognitive behavioral therapy; Ftf = face-to-face; Gsh = guided self-help; IPT = interpersonal therapy; Nmc= no/minimal contact; PDT = psychodynamic therapy; PST = problem solving therapy; Rtl = remote
therapist-lead; SSRI = selective serotonin reuptake inhibitors; TCA = tricyclic and tetracyclic antidepressants; UC = usual care













Table 3 Pairwise treatment comparisons from network meta-analyses for the outcomes post-treatment depression scores (above the diagonal) and study discontinuation (below
the diagonal)
Ftf CBT 0.18 0.21 0.00 0.02 −0.02 −0.16 −0.04 0.06 −1.31 −0.17 0.08 0.05 0.11 −0.02 0.34
−0.09–0.44 −0.07–0.50 −0.66–0.67 −0.21–0.25 −0.25–0.20 −0.88–0.55 −0.31–0.22 −0.20–0.33 −2.15–(−0.47) −0.69–0.35 −0.29–0.46 −0.22–0.32 −0.19–0.41 −0.56–0.53 0.16–0.51
1.47 Ftf PST 0.04 −0.17 −0.16 −0.20 −0.34 −0.22 −0.11 −1.48 −0.35 −0.09 −0.13 −0.06 −0.19 0.16
0.65–3.51 −0.23–0.31 −0.81–0.47 −0.42–0.11 −0.48–0.08 −1.06–0.38 −0.50–0.06 −0.39–0.17 −2.31–(−0.66) −0.81–0.12 −0.44–0.25 −0.34–0.09 −0.36–0.24 −0.76–0.37 −0.04–0.36
0.98 0.67 Ftf IPT −0.21 −0.19 −0.24 −0.38–1.11– −0.26 −0.15 −1.52 −0.38 −0.13 −0.16 −0.10 −0.23 0.12
0.30–3.11 0.25–1.70 −0.86–0.44 −0.48–0.09 −0.54–0.06 0.35 −0.56–0.05 −0.45–0.15 −2.36–(−0.69) −0.90–0.14 −0.44–0.17 −0.41–0.08 −0.40–0.19 −0.81–0.34 −0.11–0.35
1.72 1.17 1.75 Ftf PDT 0.02 −0.03 −0.17 −0.05 0.06 −1.31 −0.17 0.08 0.05 0.11 −0.02 0,33
0.24–15.2 0.18–9.32 0.25–14.41 −0.65–0.68 −0.70–0.64 −1.11–0.78 −0.72–0.62 −0.61–0.73 −2.31–(−0.31) −0.95–0.60 −0.60–0.75 −0.56–0.65 −0.57–0.79 −0.85–0.81 −0,31–0,97
0.99 0.67 1.01 0.58 Ftf Other −0.04 −0.19 −0.06 –0.33– 0.04 −1.33 −0.19 0.06 0.03 0.09 −0.04 0.31
0.48–2.12 0.27–1.59 0.34–3.07 0.07–4.46 −0.30–0.21 −0.90–0.53 0.20 −0.22–0.30 −2.17–(−0.49) −0.71–0.33 −0.31–0.43 −0.24–0.30 −0.20–0.39 −0.54–0.46 0.14–0.49
1.75 1.19 1.79 1.02 1.77 Rtl CBT −0.14 −0.02 0.09 −1.29 −0.15 0.11 0.07 0.14 0.01 0.36
0.67–4.46 0.36–3.51 0.50–6.34 0.09–7.89 0.59–5.14 −0.86–0.58 −0.30–0.26 −0.19–0.36 −2.13–(−0.44) −0.68–0.38 −0.28–0.49 −0.21–0.36 −0.18–0.45 −0.55–0.57 0.17–0.55
0.74 0.51 0.76 0.43 0.75 0.42 Rtl PST 0.12 0.23 −1.14 0.00 0.25 0.22 0.28 0.15 0.50
0.17–3.23 0.11–2.22 0.15–3.32 0.04–4.66 0.18–3.21 0.08–2.17 −0.60–0.84 −0.49–0.95 −2.22–(−0.07) −0.86–0.85 −0.52–1.02 −0.51–0.94 −0.46–1.02 −0.72–1.02 −0.19–1.19
0.62 0.42 0.63 0.36 0.63 0.35 0.83 Gsh CBT 0.11 −1.26 −0.13 0.13 0.09 0.16 0.03 0.38
0.24–1.46 0.16–1.00 0.20–1.88 0.04–2.81 0.25–1.56 0.11–1.08 0.19–3.80 −0.17–0.39 −2.11–(−0.42) −0.66–0.41 −0.26–
0.51
−0.20–0.38 −0.17–0.48 −0.54–0.59 0.18–0.58
0.66 0.45 0.68 0.39 0.67 0.38 0.89 1.07 Nmc CBT −1.37 −0.23 0.02 −0.01 0.05 −0.08 –0.64– 0.27
0.21–2.08 0.15–1.37 0.19–2.16 0.04–3.48 0.23–1.96 0.102–1.43 0.18–4.43 0.35–3.46 −2.22–(−0.53) −0.76–0.30 −0.37–0.40 −0.30–0.2 −0.27–0.37 0.48 0.07–0.47
No data No data No data No data No data No data No data No data No data Ftf CBT +
SSRI
1.14 1.39 1.36 1.42 1.29 1.64
0.21–2.07 0.54–2.24 0.56–2.16 0.57–2.27 0.31–2.27 0.82–2.47
2.04 1.39 2.08 1.19 2.06 1.16 2.74 3.29 3.07 No data Ftf PST +
SSRI
0.25 0.22 0.28 0.15 0.50
0.40–9.99 0.34–5.61 0.40–10.65 0.12–12.2 0.40–9.90 0.20–6.44 0.31–20.2 0.65–18.1 0.56–16.7 −0.31–
0.81
−0.26–0.70 −0.26–0.82 −0.57–0.88 0.01–1.00
1.54 1.05 1.58 0.90 1.56 0.88 2.07 2.49 2.32 No data 0.76 Ftf IPT +
SSRI
−0.03 0.03 −0.10 0.25
0.38–6.64 0.29–4.04 0.50–5.10 0.09–7.19 0.39–6.64 0.18–4.16 0.33–13.7 0.55–10.5 0.48–12.5 0.13–4.68 −0.33–0.27 −0.36–0.42 −0.72–0.53 −0.08–0.58
1.26 0.86 1.29 0.73 1.27 0.72 1.69 2.03 1.90 No data 0.62 0.82 SSRI 0.06 −0.07 0.28
0.52–3.18 0.44–1.76 0.53–3.20 0.11–4.10 0.51–3.45 0.22–2.39 0.39–8.14 0.74–5.83 0.60–6.77 0.16–3.11 0.26–2.73 −0.24–0.37 −0.64–0.50 0.08–0.49













Table 3 Pairwise treatment comparisons from network meta-analyses for the outcomes post-treatment depression scores (above the diagonal) and study discontinuation (below
the diagonal) (Continued)
0.45–5.36 0.37–3.10 0.57–4.37 0.09–7.67 0.50–5.56 0.22–3.54 0.40–11.0 0.70–9.17 0.70–9.57 0.13–4.10 0.23–4.25 0.39–3.90 −0.71–0.45 −0.03–0.48
2.01 1.37 2.06 1.17 2.03 1.15 2.71 3.25 3.04 No data 0.99 1.31 1.60 1.30 Individ..
Antid.
0.35
0.40–9.46 0.25–7.50 0.32–11.74 0.08–12.9 0.46–8.52 0.18–6.73 0.35–19.8 0.57–18.5 0.47–18.4 0.10–9.23 0.17–9.78 0.26–8.45 0.21–8.41 −0.18–0.88
1.00 0.68 1.03 0.59 1.01 0.57 1.35 1.62 1.51 No data 0.49 0.65 0.80 0.65 0.50 UC/
placebo
0.57–1.86 0.34–1.27 0.40–2.39 0.08–4.08 0.56–1.86 0.22–1.45 0.36–5.16 0.80–3.24 0.60–3.76 0.11–2.22 0.18–2.33 0.36–1.60 0.21–1.76 0.11–2.48
With regard to post-treatment depression scores, standardized mean differences above 0 favor the row-defining treatment, and below 0 the column-defining treatment. With regard to study discontinuation, odds ratios smaller
than 1 favor the column-defining treatment, and odds ratios lower than 1 favor the row-defining treatment. Reciprocals should be used to obtain odds ratios in the opposite direction. Bold-faced figures indicate a difference
between treatments with 95 % credible intervals of estimates excluding 1. For abbreviations see Table 2
The results are standardized mean differences (post-treatment depression scores with 95 % confidence intervals) and odds ratios (study discontinuation with 95 % credible intervals) when comparing the column-













from the study, treatment discontinuation, missing out-
come data). Network meta-analysis did not reveal any
differences between treatments, but 95 % credible inter-
vals were wide (Table 3 below the diagonal).
Discussion
Our findings show that while a number of randomized
trials have investigated psychological treatments for de-
pression in primary care patients it is yet difficult to de-
cide whether some treatments should be considered
more effective than others. In network meta-analyses
face-to-face CBT, other face-to-face therapies (mainly
counselling approaches), remote therapist lead CBT,
guided self-help CBT, and no/minimal contact CBT
were superior to usual care or placebo. Face-to-face PST,
face-to-face interpersonal psychotherapy, face-to-face
psychodynamic therapy, and remote therapist-lead PST
were not different from usual care or placebo, but the
last two treatments have been investigated in very few
patients. With one exception (remote therapist-lead
CBT was superior to face-to-face interpersonal psycho-
therapy), there were no differences between the single
treatments, but credible intervals of effect estimates
were often too wide to rule out that clinically relevant
differences exist. For CBT, a variety of different delivery
approaches have been investigated and the findings
suggest that less resource-intensive interventions have
similar effects as “traditional” face-to-face CBT.
To the best of our knowledge, this is the first network
meta-analysis of primary care trials comparing different
psychological treatments for depression. Compared to
our conventional meta-analysis of 30 trials of psycho-
logical treatment vs. usual care [11], the network meta-
analysis in this article used the available data from
randomized trials in a much more comprehensive man-
ner. In does not only include seven additional trials not
having a usual care control group but also comparisons
with other treatment options in trials with such a con-
trol group. For example, for the outcome response, the
analysis in our standard meta-analysis covered 27 compar-
isons with usual care, while the network meta-analysis
integrated further 24 comparisons with other treatment
options. In principle, this broader evidence base should
allow a better assessment of the comparative effectiveness
of psychological treatment for depressive disorders. We
assessed carefully whether assumptions (homogeneity,
consistency and transitivity – see methods section) under-
lying network meta-analysis were met. The homogeneity
and consistency assumptions were met sufficiently in our
analyses, but due to the limited number of trials for most
comparisons, power of these tests was rather low and
impaired sensitivity of the investigations [34]. Statistical
heterogeneity and inconsistency were low with few
minor exceptions. However, we fear that the transitivity
assumption is not fully met. Transitivity more or less
assumes that patients could be randomized to any of
the treatment arms in the network. Transitivity is vio-
lated when the treatment in question differs systematic-
ally between trials, not randomly [13]. Five of the six
trials in patients with minor depression and/or dys-
thymia investigated problem-solving therapy. Trials
limited to patients with major depression more often
investigated face-to-face therapies. Studies testing a
certain delivery mode might be more likely to recruit
participants who are motivated to use specifically this
treatment mode and not another. For example, patients
preferring face-to-face psychotherapy might be less
likely to embark on and comply with a no/minimal
contact treatment (and vice versa). Furthermore, while
most trials insufficiently reported what exactly hap-
pened in usual care groups, it seems possible that there
was systematic variation here, too. We still think that
performing network-analysis was justifiable, but its
findings have to be interpreted with caution. The
doubts regarding transitivity were a major reason for us
to publish our conventional meta-analysis of pairwise
comparisons with usual care controls in detail first [11].
Still, the findings of both our approaches to analyse the
available database are highly consistent.
Our findings are also consistent with those of the large
network meta-analysis by Barth et al. [5] including
mostly trials from specialized mental health care. Effect
sizes over usual care were small to moderate and differ-
ences between different psychological treatments were
small to absent. This suggests that findings of trials in
more specialized settings do not differ fundamentally
from those of primary care trials. Our findings are also
consistent with two recent conventional meta-analyses
of primary care trials of psychological treatments for
anxiety and depression [35, 36]. An important new fea-
ture of our review is the systematic investigation of dif-
ferent delivery modes. According to our meta-analysis,
up to now sufficient evidence is only available for CBT,
suggesting that its effectiveness is only minimally im-
paired by reducing the number of contacts with health
care professional and by using remote administration in
primary care. The formal comparisons of face-to-face
with remote/limited contact CBT suggesting comparable
effectiveness were sufficiently precise, largely consistent,
and were based on a substantial number of trials, of
which several were judged to be at a low risk of bias.
However, the network meta-analytical effect estimates
were almost exclusively based on indirect comparisons
(mainly with usual care as the common comparator),
may be somewhat biased due to possible publication
bias, and might not fulfil the criterion of transitivity. In
summary, although existing evidence suggests equal
effectiveness of different delivery modes of CBT in
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primary care, confidence in this finding should remain
limited until confirmed in direct head-to-head trials.
The network meta-analysis by Barth et al. [5] did not
find a difference between individualized face-to-face and
all other delivery modes. However, this finding is diffi-
cult to interpret as an unclear number of studies using
face-to-face group interventions were compared with
an unclear number of pooled studies on limited or no
contact interventions. The results on face-to-face
interpersonal psychotherapy are somewhat discouraging
showing little to no benefit over usual care unless it is
combined with pharmacotherapy. This finding upholds
the conflicting evidence base of this treatment including
both supportive [37] and sceptical [38] pieces of infor-
mation. In the present study, network meta-analytical
effect estimates from three large trials comparing inter-
personal therapy with active medication or usual care
and from indirect comparisons were acceptably precise
and consistent, but two of the trials were judged to be
at high risk of bias. Thus, our global confidence in the
obtained findings on interpersonal therapy in primary
care was moderate and calls for further research on this
treatment. The reduced effectiveness of psychological
interventions in patients with dysthymia/minor depres-
sion is in agreement with current evidence [38]. How-
ever, whether this finding is the result of the minor
severity of the disorder, its chronicity, or a combination
of both factors remains still to be clarified.
Our network also includes three combinations of psy-
chological face-to-face treatments and drug treatments.
However, each of these combinations has been tested
only in a single trial, two of which were very small. Our
analyses suggest a marked superiority face-to-face CBT
combined with SSRI treatment over all other treatments,
but this extraordinary finding from only one small trial
should be interpreted with greatest caution unless con-
firmed by large trials. Clearly; the available evidence does
not allow any firm conclusions on the value of combin-
ation treatments in depressed primary care patients. Tri-
als testing pharmacological treatment as sole treatment
were eligible to our review only if they also included a
group receiving a psychological treatment. Therefore,
our analyses can provide only a crude estimate of how
psychological treatments compare to pharmacotherapy.
Further research should be driven by the identified
evidence gaps. In our meta-analysis, the main scaffold of
the evidence base is a star-shaped network of interven-
tions with usual care/placebo as the “golden common
comparator”, with which single interventions are con-
trasted. Comparing active treatments in such a network
relies not only strongly on the questionable transitivity
assumption but also precludes reliable testing of incon-
sistency. Instead of performing trials that compare suffi-
ciently investigated interventions (e.g., face-to-face CBT)
with an established reference (e.g., usual care), head to
head randomized comparisons of clinically heteroge-
neous treatments would be desirable that systematically
vary not only the theoretical background but also the
intensity of the contact with health care professional and
the delivery mode (face-to-face vs remote, including
different forms of the technical realization). This would
allow for comparing the wide variety of psychological in-
terventions in primary care without confounding of pos-
sible (self-)selection processes in the treatment-seeking
population. Thus, primary care investigators of psycho-
logical interventions are encouraged to overcome the
“legitimation” approach of comparing specific interven-
tions with non-specific reference treatments and embark
on the comparative effectiveness research perspective
looking for answers that truly inform decision-making
under routine conditions [39].
Conclusions
Based on the limited available evidence, it is difficult to
assess the comparative effectiveness of psychological
treatments in depressive primary care patients with high
confidence. Although any conclusion can only be tenta-
tive, findings suggest that psychological interventions
with a cognitive behavioral approach are promising for
the treatment of primary care patients with depression.
Primarily indirect evidence with moderate confidence
indicates that this is also true when the cognitive behav-
ioral therapies are delivered with a reduced number of
therapist contacts or remotely. Further large trials com-
paring psychological treatments with each other, with
pharmacotherapy, and combinations of psychological
and drug treatments under conditions of routine pri-
mary care are highly desirable.
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